Gilles Avenard, MD – CEO
Board member or advisor for several biotech companies ; co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. Gilles Avenard was involved in the development of several innovative medicines until their registration in Europe and the USA. Before that, he was Projects Director for Hoechst Marion Roussel (Sanofi) and Medical Director of Bio-Transfusion (LFB).
Olivier Favre Bulle, PhD – COO
Founder of 3Biotech, specialized in Pharmaceutical Development of Large and Small molecules. Site manager and European Head of Drug Development for Covance, Olivier also was head of NNE Pharmaplan France, a subsidiary of Novo Nordisk. He started at Rhône-Poulenc as Project Manager in Biological Drugs development. Chemical Engineer by training with a Ph.D in Bioengineering.
Yannick Plétan, MD – CMO
Dr Plétan is an expert in clinical development within the pharmaceutical industry, having previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre. Before joining Acticor Biotech, Dr Plétan served as Head of Medical Division and Member of the Board of the Foundation at Roche France and Member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland). Previously, he was Vice-President, Head of Medical and Scientific Division and Member of the Board of the Foundation at Pfizer.
Eric Cohen, MBA – Finance Advisor
CEO and Founder of Agile Capital Markets; Advisor of several biotech & medtech companies; Investor Relations for Cellnovo Group. Eric was CFO of Mauna Kea Technologies (Euronext®: MKEA), Hybrigenics (Euronext®: ALHYG) and Teva Pharmaceuticals France (NASDAQ®: TLV) . He lead 2 IPO on Euronext® and several private and public financing round. He was also Head of Hybrigenics Business Services and Head of Operations (R&D and Production) at Mauna Kea.